AVITA Medical, Inc. (RCEL) Misses Q2 EPS by 10c

AVITA Medical, Inc. (NASDAQ: RCEL) reported Q2 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.75 million versus the consensus estimate of $11.3 million.

GUIDANCE:

AVITA Medical, Inc. sees Q3 2023 revenue of $13-14 million.

For earnings history and earnings-related data on AVITA Medical, Inc. (RCEL) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight